Jazeta (Sitagliptin Hydrochloride)

Sitagliptin works by reversibly inhibiting the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, sitagliptin enhances glucose‑dependent insulin secretion and reduces glucagon release, leading to lower post‑prandial and fasting blood glucose levels.

The prescribed dose of Jazeta is determined by the treating physician based on individual patient factors such as renal function, concomitant medications, and glycaemic targets. Clinicians typically start with a standard dose and may adjust it according to therapeutic response and tolerability, following local prescribing guidelines.

Safety data for sitagliptin in pregnancy and lactation are limited. Current guidelines advise that it should only be used during pregnancy or while breastfeeding if the potential benefit justifies the potential risk to the fetus or infant. Healthcare providers should discuss alternative treatment options and closely monitor maternal and fetal health.

To order Jazeta, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with sulfonylureas, sitagliptin offers a lower risk of hypoglycaemia because its insulin‑secretory effect is glucose‑dependent. Unlike insulin, it is an oral agent and does not require injection. Relative to GLP‑1 receptor agonists, sitagliptin is less potent in weight reduction but has a more convenient oral dosing schedule.

Jazeta tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, heat and direct sunlight. Do not store in the bathroom or near a kitchen sink, and keep out of reach of children.

Jazeta is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water. Patients should follow the dosing schedule prescribed and not alter the timing or frequency without medical advice.

The most serious adverse events reported with sitagliptin include acute pancreatitis, severe hypersensitivity reactions such as anaphylaxis or angioedema, and acute renal failure, particularly in patients with pre‑existing kidney disease. Prompt medical attention is required if patients experience persistent severe abdominal pain, rash, swelling, or sudden loss of kidney function.

Jazeta should be avoided in patients with a known hypersensitivity to sitagliptin or any component of the formulation. Caution is advised in individuals with severe renal impairment, a history of pancreatitis, or uncontrolled heart failure. The drug is not recommended for type 1 diabetes or for diabetic ketoacidosis.